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Introduction: Mucopolysaccharidosis type I (MPS I) is a progressive multisystem lysosomal storage disease caused
by deficiency of the enzyme α-L-iduronidase (IDUA). Patients present with a continuous spectrum of disease
severity, and the most severely affected patients (Hurler phenotype; MPS I-H) develop progressive cognitive
impairment. The treatment of choice for MPS I-H patients is haematopoietic stem cell transplantation, while
patients with the more attenuated phenotypes benefit from enzyme replacement therapy.
The potential of newborn screening (NBS) for MPS I is currently studied in many countries. NBS for MPS I, however,
necessitates early assessment of the phenotype, in order to decide on the appropriate treatment. In this study, we
developed an algorithm to predict phenotypic severity in newborn MPS I patients.
Methods: Thirty patients were included in this study. Genotypes were collected from all patients and all patients
were phenotypically categorized at an age of > 18 months based on the clinical course of the disease. In 18 patients,
IDUA activity in fibroblast cultures was measured using an optimized IDUA assay. Clinical characteristics from the first
month of life were collected from 23 patients.
Results: Homozygosity or compound heterozygosity for specific mutations which are associated with MPS I-H,
discriminated a subset of patients with MPS I-H from patients with more attenuated phenotypes (specificity 100%,
sensitivity 82%). Next, we found that enzymatic analysis of IDUA activity in fibroblasts allowed identification of patients
affected by MPS I-H. Therefore, residual IDUA activity in fibroblasts was introduced as second step in the algorithm.
Patients with an IDUA activity of < 0.32 nmol x mg-1 × hr-1 invariably were MPS I-H patients, while an IDUA activity
of > 0.66 nmol × mg-1 × hr-1 was only observed in more attenuated patients. Patients with an intermediate IDUA
activity could be further classified by the presence of differentiating clinical characteristics, resulting in a model with
100% sensitivity and specificity for this cohort of patients.
Conclusion: Using genetic, biochemical and clinical characteristics, all potentially available in the newborn period, an
algorithm was developed to predict the MPS I phenotype, allowing timely initiation of the optimal treatment strategy
after introduction of NBS.
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Mucopolysaccharidosis type I (MPS I, OMIM 252800) is
a progressive multisystem lysosomal storage disease
(LSD) caused by a deficiency of the lysosomal hydrolase
α-L-iduronidase (IDUA, [Genbank NG_008103]), re-
sulting in the accumulation of the glycosaminoglycans
heparan sulfate (HS) and dermatan sulfate (DS) in virtu-
ally all body tissues [1]. MPS I encompasses a wide
phenotypic spectrum, with at the severe end the Hurler
phenotype (MPS I-H), which is the most prevalent
phenotype, characterized by progressive central nervous
system disease in addition to the most prominent som-
atic manifestations: severe musculoskeletal, pulmonary
and cardiac disease, inguinal and umbilical hernias and
corneal clouding, all resulting in a significantly reduced
life expectancy if left untreated [2-5]. Patients with the
intermediate Hurler-Scheie phenotype (MPS I-H/S) are
generally reported as having only mild or no cognitive
impairment but relatively severe somatic symptoms that
limit life expectancy to the 2nd or 3rd decade in the ab-
sence of treatment, while the attenuated Scheie pheno-
type (MPS I-S) is characterized by relatively milder
somatic manifestations and a near normal life expect-
ancy [5,6].
Two disease modifying treatment options are currently
available in MPS I: hematopoietic stem cell transplant-
ation (HSCT) and intravenous enzyme replacement
therapy (ERT) [7]. HSCT can stabilize neurocognitive
function, significantly ameliorate the course of several of
the somatic symptoms and improve overall survival
[8-11]. HSCT is the preferred treatment strategy for pa-
tients with a presumed MPS I-H phenotype who are di-
agnosed before the age of approximately 2.5 years of age
[7]. HSCT may also be considered in patients with MPS
I-H/S who display progressive neurocognitive involve-
ment [7]. However, although outcomes have improved
considerably [12], HSCT still carries a considerable risk
for procedure-related morbidity and mortality. Weekly
ERT with recombinant IDUA (Laronidase ®) is, therefore,
the preferred treatment for patients with the more atten-
uated phenotypes (MPS I-S and, in general, MPS I-H/S)
and ERT was shown to improve respiratory and cardiac
symptoms of MPS I and some of the skeletal and joint
manifestations, reduce hepatosplenomegaly, and im-
prove the overall quality of life [13-18].
As early initiation of the optimal treatment, either
HSCT or ERT, is highly likely to improve clinical out-
comes [8,9,11,19], early diagnosis is essential. However,
the variable clinical expression and the nonspecific signs
and symptoms, in combination with the rarity of the dis-
order, often lead to a long diagnostic delay [3]. Popula-
tion newborn screening (NBS), using dried blood spots
for detection of MPS I [20-23], is probably the best ap-
proach to identify patients at a very young age, thusallowing timely initiation of treatment. The feasibility of
inclusion of MPS I in NBS programs is currently studied
in several countries [24-26]. Early diagnosis of MPS I
through NBS, however, requires early prediction of the
phenotype in each MPS I patient to guide decisions on
the optimal treatment strategy. To date, assessment of
the phenotype is generally based on signs and symptoms
at clinical presentation and age of disease onset [15], as
genotype is often not informative [27,28]. A recent
study, initiated by our group, revealed a lack of consen-
sus between experts on the assessment of phenotypic se-
verity using a scale from 0 to 10, based solely on signs
and symptoms at presentation [29]. This may be even
more complicated within the scope of a NBS program,
as patients may still lack many of the characteristic
symptoms on which phenotyping is currently based. In
addition to clinical and genetic characteristics, biochem-
ical predictors have been sought to distinguish between
phenotypes, but studies so far have been unsuccessful
[30,31], except for one study by Fuller et al. [32]. The
assay reported in this latter study, however, is rather
complex and requires the availability of specific anti-
bodies which renders it difficult to implement in other
laboratories.
As NBS for MPS I may be implemented in several
countries within the near future, there is an urgent need
for a tool which allows reliable prediction of the pheno-
type within the first months of life. Here we present an
algorithm for early determination of phenotypic severity
in patients with MPS I diagnosed through NBS, combin-
ing mutational analysis, determination of residual en-
zyme activity in cultured skin fibroblasts and clinical
characteristics that are apparent within the first month
of life. This algorithm may allow separation of those
MPS I patients who will benefit from HSCT at an early
age from those that will optimally benefit from an early
start of ERT.Methods
Outline of the prediction algorithm
We decided to design our algorithm on the separation
of two distinct phenotypic categories based on the indi-
cations for treatment: patients with MPS I-H, who will
benefit from early HSCT and more attenuated non-MPS
I-H patients (MPS I-H/S and S), who will benefit from
early start of ERT and for whom HSCT is, in general,
not considered the optimal treatment strategy [7]. To
this aim, we collected data that can all be assessed
within the first month of life and might be related to the
phenotypic severity: genotype, residual enzymatic activity
and GAG storage in cultured skin fibroblasts and clinical
signs and symptoms that may become apparent in the
first month of life.
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Thirty patients with MPS I, who were diagnosed and
treated in the Academic Medical Centre, Amsterdam,
the Netherlands, were included in this study. All patients
were classified into three categories (MPS I-H, MPS
I-H/S and MPS I-S) by one of the authors (FAW), a clin-
ician experienced in the diagnosis and treatment of lyso-
somal storage disorders including MPS I. Classification
was based on the clinical signs and symptoms at diag-
nosis and the clinical course of the disease, and not
on genotype, biochemical variables or clinical signs in
early life.
Mutation analysis
Mutation analysis had been performed in all 30 patients
by standard procedures within the scope of the normal
diagnostic workup at our centre. Missense, nonsense,
splice site mutations, insertions and deletions were iden-
tified. Based on literature [10,27,33-41], potentially dis-
criminating genotypes were identified.
Residual IDUA activity
Fibroblasts
Fibroblast cultures were available from 18 of the 30 pa-
tients included in this study. Informed consent for the
use of fibroblasts for these studies was obtained from all
patients or parents.
Cell culture
To remove bovine IDUA activity from the Fetal Bovine
Serum (FBS), FBS was inactivated by incubation at 56°C
for 30 minutes before use. Patient and control fibroblasts
were grown in Dulbecco’s Modified Eagle's Medium
supplemented with 10% inactivated FBS and 100 U × ml-1
penicillin, 100 μg × ml-1 streptomycin and 250 μg × ml-1
amphotericin in a humidified atmosphere containing 5%
CO2 at 37°C. Fresh medium was added every 2 weeks.
After culture for 1, 2, 4, 6, 8 or 10 weeks postconfluency,
the medium was removed, cell layers were washed with
phosphate buffered saline (PBS) and harvested. Cell pellets
were washed once with PBS, twice with 0.9% NaCl and
stored at −20°C until analysis.
IDUA activity analysis
The generally used method to measure residual IDUA ac-
tivity, using 4-methylumbelliferyl-α-L-iduronide (Glycosynth
Ltd., Warrington, Cheshire, England) as substrate [42,43],
was optimized by varying the quantity of cell lysate, time
of incubation and amount of substrate in order to accur-
ately determine very low enzyme activities in MPS I pa-
tient fibroblasts.
Cells were resuspended in PBS and disrupted by
sonification using a Vibra Cell sonicator (Sonics & Materials
Inc., Newtown, CT, USA). Protein concentration wasmeasured in whole cell lysates as described by Lowry et al.
[44]. 20 μl of cell lysate was added to 4-methylumbelliferyl-
α-L-iduronide in 0.1 M sodium formiate buffer, with a final
volume of 60 μl, a final 4-methylumbelliferyl-α-L-iduronide
concentration of 1mM and a final protein concentration of
0.5 mg × ml-1. After 2 hours of incubation at 37°C, the reac-
tion was stopped by addition of 1440 μl 0.2 M sodium
carbonate/glycine buffer, pH 10.5. Released 4-methylumbe-
lliferone was measured fluorometrically with an excitation
wavelength of 366 nm and an emission wavelength of
442 nm using a Perkin Elmer LS45 fluorescence spec-
trometer (Perkin Elmer, Waltham, MA, USA). IDUA
activity in each sample was calculated using a calibra-
tion curve of 4-methylumbelliferone (Glycosynth Ltd.,
Warrington, Cheshire, England). All enzyme activity as-
says were performed in duplicate and repeated at least
once in independent cell cultures. Earlier experiments in
our laboratory, using control fibroblasts, showed an intra-
assay variation of 1.4% and an inter-assay variation of
18.5%. To control for this relatively large inter-assay vari-
ation, with each performed IDUA assay, IDUA activity
was simultaneously determined in at least 4 other previ-
ously analyzed cell lines, to make sure that the results
from different experiments could be reliably compared.
Glycosaminoglycan (GAG) analysis in fibroblasts
Levels of HS and DS were determined as described pre-
viously [45] with minor modifications. GAGs in 25 μg of
fibroblast lysate (prepared as described for the IDUA ac-
tivity analysis) were enzymatically digested into disac-
charides and as a final deproteination step samples were
loaded on an Amicon Ultra 10 kD centrifugal filter
(EMD Millipore, Billerica, MA, USA) (instead of a 30kD
filter), and centrifuged at 14.000 g for 30 minutes on 25°C.
Clinical characteristics
There are currently only few data published on clinical
signs and symptoms in MPS I patients at birth or within
the first month of life [46,47]. Therefore, we decided to
study the absence or presence of 14 clinical signs and
symptoms (Table 1) which are reported as early presenting
symptoms in MPS I [46-49]. As several MPS I-H-related
clinical characteristics develop only later in life, such as
developmental delay and stunted growth, these were not
included in our study. If information on certain clinical
signs was not available in the charts, parents of the pa-
tients were contacted by telephone and additional infor-
mation was added to the information retrieved from the
charts. All characteristics were scored as absent, present,
or data not available (Table 2). Clinical characteristics
from patients born before 37 weeks of gestational age were
excluded, as symptoms related to prematurity, such as re-
spiratory complications or increased occurrence of in-
guinal hernias may be confounding.
Table 1 Clinical characteristics scored in the patient cohort









Umbilical hernia 18 0.6





Stiff joints/contractures 2 X
Kyphosis 1 X
Scoliosis 1 X
Hip dysplasia 1 X
Other




Corneal clouding 0 X
X = insufficient data available for statistical analysis.
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tween MPS I-H and MPS I-non Hurler patients were
considered distinguishing and considered for the predic-
tion algorithm.Statistics
Statistical analysis was performed using the SPSS Statis-
tics software version 19 (IBM Corp., Armonk, NY, USA).
Nonparametric ranking statistics (Mann–Whitney-U tests)
were used to analyze the relationship between the
assigned MPS I phenotypes (MPS I-H versus non-MPSI-
H) and residual IDUA activity and GAG levels in fibro-
blasts. The most efficient cut-off values to discriminate
between MPS I phenotypes based on IDUA activity were
identified using receiver operating characteristic (ROC)
curve analysis. True positive rates (sensitivity) were plotted
against false positive rates (1-specificity) for all classifica-
tion points, and p-values were calculated for the area
under the curve.
Differences between the phenotypic groups (MPS I-H
versus non-MPS I-H) in the frequency of specific muta-
tions or clinical characteristics were assessed either by
Fisher’s exact test (dichotomous variables) or Mann–
Whitney-U test (numeric variable).A three-step algorithm was designed and discrimin-
ation of the three phases in the flow chart was assessed
separately by calculating sensitivity and specificity. This
was also done for the algorithm as a whole, as a way to
perform internal validation.
All p-values were based on two-sided testing and dif-
ferences with p-values < 0.05 were considered statisti-
cally significant.
Results
For all 30 patients with MPS I included in this study, in-
formation on at least one potentially predictive criterion
(genetic, biochemical or clinical) was available.
Mutation analysis
Based on the literature [10,27,33-41], a list of 25 muta-
tions, which have been shown to reliably predict a
Hurler phenotype when patients are homozygous or com-
pound heterozygous for these mutations, was constructed
(Table 3). In our cohort, the association of these mutations
with MPS I-H could be confirmed for the mutations p.
Q70X, p.W402X, p.L218P and c.134del12.
As mutations that have been associated with the more
attenuated phenotypes [30,37,50] may be more suscep-
tible to the effects of modifying polymorphisms in other
genes [50], these mutations were not included in our al-
gorithm. Using the list of predictive mutations in Table 3
in our group of 30 patients, a specificity of 100% for pre-
diction of the MPS I-H phenotype and a sensitivity of
82% was calculated. The list of predictive mutations was
integrated as first step in the prediction algorithm.
Biochemical analyses
Residual IDUA activity
Figure 1 shows that IDUA enzyme activity was linear up
to at least 120 minutes of incubation time (Figure 1A) and
0.5 mg × ml-1 final protein concentration (Figure 1B).
Based on these findings, we selected these conditions for
subsequent studies. Substrate titrations were performed
(Figure 1C) and although maximal enzyme activity was
not reached, subsequent activity measurements were
performed using a final substrate concentration of 1 mM.
This concentration resulted in a 45% increase in activity,
as compared to the commonly used substrate concentra-
tion [42,43].
IDUA activity was determined in human skin fibro-
blast cell lines from the 18 MPS I patients (Table 2 and
Figure 2) of whom cell lines were available. Analyses
were performed a week after the cells had reached
confluency.
Residual IDUA activity in MPS I cell lines ranged from
0.23-2.43 nmol × mg-1 × hr-1 (Table 2), which is less
than 2.5% of the activity found in control fibroblasts
(control range: 101–270 nmol × mg-1 × hr-1). MPS I-H
Table 2 Patient characteristics
General information Genetic characteristics Biochemical characteristics Clinical characteristics












1 H 37 + 0 p.W402X p.W402X 0.31 - +
2 H 38 + 1 p.W402X p.Q70X X - +
3 H 40 + 0 p.W402X p.Q70X X X X
4 H 39 + 6 p.W402X p.W402X 0.25 + -
5 H 37 + 5 p.W402X c.134del12 0.26 X -
6 H 33 + 6 p.Q70X p.L218P 0.47 X X
7 H 33 + 1 p.Q70X p.L218P 0.44 X X
8 H 38 + 0 p.Q70X p.L218P 0.58 + X
9 H 37 + 2 p.Q70X p.L218P X + -
10 H X p.W402X p.L218P X + X
11 H 33 + 0 p.L218P p.L218P X X X
12 H 40 + 0 p.L218P p.L218P X + -
13 H 38 + 3 p.W402X p.L218P 0.43 + -
14 H 41 + 1 p.A367E c.1650del117 X + +
15 H 38 + 1 c.494-1G > A c.494-1G > A 0.23 X +
16 H X p.H425fs p.H425fs 0.32 X X
17 H 40 + 0 p.W402X p.W402X X X X
18 H/S 40 + 0 p.W402X p.R505G 0.77 + -
191 H/S 38 + 0 p.W402X p.N348K 0.92 - -
201 H/S 37 + 1 p.W402X p.N348K 0.95 - -
21 H/S 41 + 2 p.L218P p.D315Y 0.35 - -
222 H/S 37 + 0 p.P533R p.P533R X - -
232 H/S 37 + 0 p.P533R p.P533R 2.43 - -
24 S 40 + 0 p.W402X p.R383H 1.05 - -
253 S 40 + 0 p.Q70X p.R383H 1.17 X X
263 S 40 + 0 p.Q70X p.R383H X X X
27 S X p.A327P p.R383H 1.70 X X
284 S 40 + 5 c.474-2A > G p.R383H X - -
294 S 40 + 5 c.474-2A > G p.R383H 1.61 - -
30 S 40 + 0 c.474-2A > G p.R383H X - -
H = Hurler, H/S = Hurler/Scheie, S = Scheie.
+ = present, - = absent, X = data not available or excluded based on prematurity.
1,3,4: siblings. 2: homozygous twins.
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MPS I-S fibroblasts (p < 0.01) based on IDUA activity.
Most MPS I-H/S fibroblasts had an intermediate IDUA
activity (Figure 2). The diagnostic accuracy of the IDUA
assay in differentiating MPS I-H from non-H MPS I pa-
tients showed an area under the ROC curve of 0.951
(p < 0.001, Figure 3A), indicating a good discrimination.
Two cut-off values were calculated, resulting in three cat-
egories of enzyme activity: an IDUA activity of < 0.32
nmol × mg-1 × hr-1 identified MPS I-H fibroblasts with a
specificity of 100% (sensitivity 56%), as shown in Figure 3B.This was regarded as the lower threshold, as only MPS I-H
patients were found below this level of activity. Further-
more, 100% sensitivity (specificity 89%) was reached at a
cut-off value of 0.66 nmol x mg-1 × hr-1 enzymatic ac-
tivity to discriminate MPS I-H fibroblasts from cell
lines of non-H MPS I patients (Figure 3B). Subse-
quently, this was set as the upper threshold; no MPS I-
H fibroblasts had an enzyme activity higher than
0.66 nmol × mg-1 × hr-1.
The same sensitivity for discrimination of phenotypes
was obtained when cells were cultured for 2, 4, 8 or
Table 3 Mutations described as MPS I-Hurler associated
in literature
Nonsense Reference Other Reference
p.W41X [40] p.G51D [33,38]
p.Y64X [37] c.134del12 [10,34]
p.Q60X [27] p.G208V [27]
p.Q63X [37,39] p.L218P [27,34]
p.Q70X [33,37] p.A327P [27,33]
p.P201X [33] p.T366P [37]
p.E274X [37] c.704ins5 [37]
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however, residual enzyme activity in all fibroblast cell
lines decreased, as compared to cells cultured for 1 week
postconfluency (results not shown).
Heparan sulfate and dermatan sulfate levels in fibroblasts
No significant differences were seen between MPS I-H
fibroblasts and non-MPS I-H cells in total HS and DS or
in the levels of individual disaccharides (results not
shown).
Clinical characteristics
Information on clinical signs and symptoms in the first
month of life was available for 23 patients (Table 2). 3
patients, however, were excluded from the analysisTime (minutes)















































Figure 1 IDUA activity analysis. (A) Time dependence, using 1 mM subs
substrate and an incubation time of 60 minutes. (C) Substrate titration, usinbecause they were born at a gestational age < 37 weeks.
A significant difference between the incidence of signs
and symptoms of upper respiratory tract obstruction
(p = 0.005) and inguinal hernia (p = 0.033) was found be-
tween MPS I-H patients and non-MPS I-H patients.
Prediction algorithm
Mutation analysis was integrated as the first step in the
prediction algorithm (specificity 100%, sensitivity 82%)
and IDUA activity was chosen as the second step. A cut
off value of < 0.32 nmol × mg-1 × hr-1 was used to iden-
tify MPS I-H patients. An IDUA activity of >0.66 nmol ×
mg-1 × hr-1 identified non-MPS I-H patients. Patients
with IDUA activity between 0.32-0.66 nmol × mg-1 × hr-1
were further classified by the presence of either one of
the associated clinical characteristics (sensitivity 100%,
specificity 100%).
This resulted in a sensitivity and specificity of 100%
for the complete prediction algorithm. The flow chart
for the prediction algorithm is shown in Figure 4.
Discussion
Here we present an algorithm, based on the combination
of mutation analysis, residual IDUA activity and clinical
signs and symptoms during the first month of life, which
may allow early, sensitive and specific prediction of the
phenotype in MPS I patients diagnosed through NBS.
Such an algorithm can be essential as the decision to im-
plement NBS for MPS I will depend, at least in a num-
ber of countries, on the feasibility to decide on the
optimal treatment strategy at an early age. NBS for MPS
I is of high interest as early initiation of treatment, i.e.
either HSCT for patients who will develop a MPS I-H
phenotype and ERT for the non-MPS I-H patients, likely
improves the disease outcome [8,9,12,19,51], and early
diagnosis on clinical recognition can be very difficult.
To date, more than 200 different mutations in the
IDUA gene have been reported [52], and this genetic
heterogeneity partially explains the phenotypic variabilitySubstrate concentration (mM)
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Figure 2 Residual IDUA activity in MPS I fibroblasts of patients
with different phenotypes. IDUA activity for each patient is
reported in Table 1. IDUA activity was measured in duplicate in
each sample. All experiments were at least repeated once in
independent cell cultures, the results of one representative experiment
are shown. All values are mean ± standard deviation. Control range:
101–270 nmol × mg-1 × hr-1.
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phenotype correlation is known. However, some muta-
tions have been found to reliably predict a severe disease
phenotype [10,27,33-41]. This was confirmed in our co-
hort for the mutations p.Q70X, p.W402X, p.L218P and
c.134del12. Therefore, mutation analysis was included as
the first step in the algorithm to predict MPS I pheno-
type. Several missense mutations, such as the p.R383H
and p.R89Q mutations, are generally reported in associ-
ation with more attenuated disease [30,37,50]. We did
not include these latter mutations in our algorithm,
however, because the effect of attenuated mutations
might vary due to novel combinations of mutations,
polymorphisms in other genes or environmental factors
[50]. Other mutations present in our cohort were also
not incorporated in the algorithm because of functional
heterogeneity (e.g. the same mutations seem to have
a different effect on phenotypic severity) in earlierA B
Figure 3 ROC curve analysis. (A) ROC curve of IDUA activity for discrimin
for IDUA activity cut-off levels to discriminate between MPS I-H and non M
0.66 nmol × mg-1 × hr-1 IDUA activity.studies, such as the mutations p.P533R and c.474-2A >
G [27,33,37]. Studies on genotype-phenotype correla-
tions in large cohorts, focusing on allelic combinations
of rarer mutations, could further improve the predictive
power of this first step in our algorithm. Currently,
rapid mutation analysis of the IDUA gene may not be
available to all centers diagnosing MPS I. However, the
fast technological advancements for gene sequencing
will result in more universal access to mutation ana-
lysis, allowing reliable results within 4 weeks after diag-
nosis for most patients and applicability of the
algorithm presented in this study.
It is highly likely that the introduction of NBS for
MPS I will result in the identification of many novel mu-
tations with unknown phenotypes. Therefore, a tool for
prediction of phenotypic severity within the scope of
NBS needs to include other variables. We found that the
concentrations of HS and DS and of the individual disac-
charides in cultured fibroblasts did not correlate with
the phenotype. In contrast, Fuller et al. demonstrated
that the levels of specific HS and DS derived trisaccha-
rides in patient fibroblasts could discriminate between
MPS I patients with and without neurological involve-
ment [32]. In that study, only levels of short chain HS
and DS oligosaccharides were measured, while the HS
and DS derived disaccharides detected in our study ori-
ginate predominantly from relatively larger HS and DS
chains [45]. Possibly, fibroblasts from patients with
neurological involvement store more short GAGs chains,
as compared to patients without neurological symptoms,
but similar levels of larger HS and DS oligosaccharides,
which hinders discrimination between these phenotypes
using our GAG analysis.
Analyses of IDUA activity in fibroblasts or leukocytes
is generally used as the confirmatory step in MPS I diag-
nosis. However, the most commonly used method,
though sensitive for diagnostics [42,43], is not sensitive
enough to reliably discriminate between the differentation between MPS I-H and non MPS I-H. (B) Sensitivity and specificity
PS I-H. Dashed lines represent chosen cut-off levels of 0.32 and
IDUA activity¹ in fibroblastsHurler 
phenotype
Clinical characteristics
Is there one of the following signs 
or symptoms?
• Inguinal hernia (bi- or unilateral)
• Upper airway obstruction²
NOYES
<0.32 nmol
x mg ¹ x hr
0.32-0.66 nmol
x mg ¹ x hr
>0.66 nmol
x mg ¹ x hr Non-Hurler 
phenotype
Mutation analysis
Is there homozygosity/compound 
heterozygosity for mutations 




Figure 4 Algorithm for assessment of phenotypic severity in MPS I patients. Mutational analysis, residual IDUA activity and clinical
characteristics present before the age of 1 month are combined. 1Measured as described in this article. 2Upper airway obstruction included the
following symptoms: excessive snoring during sleep, continuously runny nose, obstructive sleep apneas, feeding difficulties due to obstructed
nasal breathing.
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tients [32], where the IDUA protein was first captured
using antibodies followed by enzymatic studies, showed
clear discrimination between patients with and without
neurological involvement. This method, however, makes
use of specific anti-IDUA antibodies which are not com-
mercially available, making this assay difficult to imple-
ment in other laboratories. In addition, specific putative
mutations might result in a loss of epitopes, ob-
structing capture of the protein and thus interfering
with the analysis. For this reason, we optimized the
4-methylumbelliferyl-α-L-iduronide IDUA activity assay
to provide a method that may be more generally applic-
able. A higher concentration of substrate, independently
reported by others to improve the accuracy of the IDUA
assay in a recent study [53], combined with a longer incu-
bation time and increased amount of protein, resulted in
accurate measurement of very low enzyme activities, as
seen in MPS I patients [43]. As these are minor changes
to the commonly used IDUA activity analysis protocol,
but very important to accurately determine very low IDUA
activities, we feel that most laboratories will be able to im-
plement this protocol after the necessary validation steps.
Interestingly, a very narrow range of low IDUA activities is
responsible for a broad range of clinical presentations in
MPS I patients, as IDUA activity in all MPS I fibroblasts
was less than 2.5% of the activity measured in healthy con-
trol fibroblasts. Despite this small range of IDUA activities,cut-off values could be calculated using ROC curve ana-
lysis to differentiate between MPS I Hurler and non-
Hurler fibroblasts.
Measurement of residual IDUA activity could not fully
differentiate between phenotypes of patients with an ac-
tivity in the range of 0.32-0.66 nmol × mg-1 × hr-1, as
one MPS I-H/S cell line had an IDUA activity in this
range. Although HSCT may be considered in some MPS
I-H/S patients with neurocognitive involvement [7], this
is not common practice. Therefore, the algorithm was
improved by inclusion of potentially discriminating clin-
ical characteristics early in life.
Of the 14 clinical characteristics studied, the presence
of two were found to differ significantly between MPS I-
H and non-MPS I-H MPS I patients: presence of in-
guinal hernia and the presence of signs and symptoms of
upper airway obstruction. Including clinical characteristics
in the algorithm resulted in complete differentiation be-
tween MPS I-H patients and patients with more attenu-
ated phenotypes. Another clinical characteristic that may
differentiate between MPS I-H patients and more attenu-
ated patients is probably the severity of dysostosis multi-
plex, a collection of radiographic abnormalities resulting
from defective endochondral and membranous growth
throughout the body seen in mucopolysaccharidoses. Es-
pecially thoraco-lumbar kyphosis before the age of one
month, might be a very sensitive and specific symptom for
MPS I-H [54,55]. However, early kyphosis is often initially
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fore not be included in this model, which is based on
retrospective analysis of clinical data.
Our study has some limitations. Firstly, due to the
ultra-orphan nature of the disease, the proposed algo-
rithm is validated in only a relatively small number of
patients (n = 30). Validation in other cohorts of patients
needs to be performed to further determine its value.
Secondly, our study includes a retrospective analysis of
signs and symptoms during the first month of life. This
may result in a recall bias, as both parents and investiga-
tors knew the phenotype of the patients. To address this,
only characteristics that could be clearly distinguished
and are often well documented in the newborn period
were used for this algorithm. Thirdly, the prevalence of
mutations firmly associated with certain phenotypes dif-
fers between regions around the world [37]. Therefore,
positive and negative predicting values of the proposed
algorithm may differ between countries and this needs
to be further investigated. Also, as new mutations will be
detected once NBS for MPS I has been introduced, a
prediction algorithm including mutation analysis needs
to be continuously adjusted and improved. Likewise,
NBS will allow for further investigation on the predictive
value of certain clinical signs such as early kyphosis,
which could not be included in this study.
As a result of future studies, the algorithm might be
adapted to also to differentiate between MPS I-H/S pa-
tients with and without neurocognitive involvement.
The improved outcome of HSCT, in combination with
increasing knowledge on the risk for neurocognitive de-
cline in a subset of MPS I-H/S patients, may result in a
shift in treatment protocols, with HSCT as treatment of
choice for this group of patients [7].
With the phenotypic prediction algorithm presented
here, we hope to provide the basis for a tool to reliably
predict phenotype in the majority of MPS I patients di-
agnosed through NBS. Prospective studies could result
in inclusion of additional predictive factors and improve-
ment of the prediction algorithm.Conclusion
Using genetic, biochemical and clinical characteristics,
which can all be studied within the first month of life,
an algorithm was developed for accurate prediction of
the phenotype at an early age in MPS I patients. Such an
algorithm allows timely initiation of the optimal treat-
ment strategy, thus improving disease outcome. With
the future launch of NBS programs for MPS I, patients
will not have developed all characteristic signs and
symptoms currently used for assessment of the pheno-
type, making a prediction algorithm for early assessment
of phenotypic severity indispensable.Abbreviations
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